Imperial College London
🇧🇪Belgium
- Country
- 🇧🇪Belgium
- Ownership
- Private
- Established
- 1907-07-08
- Employees
- 5K
- Market Cap
- -
- Website
- http://www.imperial.ac.uk
Individualized Dosimetry for Holmium-166 Radioembolization in Patients With Unresectable Hepatocellular Carcinoma
Not Applicable
Recruiting
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- Device: 166Holmium microspheres (QuiremSpheres®)
- First Posted Date
- 2024-03-08
- Last Posted Date
- 2024-03-08
- Lead Sponsor
- Imperial College London
- Target Recruit Count
- 15
- Registration Number
- NCT06302400
- Locations
- 🇬🇧
Imperial College Healthcare NHS Trust, London, United Kingdom
Longitudinal Assessment of Biomarkers After Oesophagogastric Cancer Surgery
Recruiting
- Conditions
- Gastric AdenocarcinomaOesophageal Adenocarcinoma
- Interventions
- Other: Biosample collection
- First Posted Date
- 2024-03-01
- Last Posted Date
- 2025-02-19
- Lead Sponsor
- Imperial College London
- Target Recruit Count
- 100
- Registration Number
- NCT06289374
- Locations
- 🇬🇧
Imperial College Healthcare NHS Trust, London, United Kingdom
Neuroinflammatory Interactions of ATP and P2X3 Receptor in the Airways of Chronic Cough Patients
Recruiting
- Conditions
- Chronic Cough
- First Posted Date
- 2024-02-29
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- Imperial College London
- Target Recruit Count
- 18
- Registration Number
- NCT06286163
- Locations
- 🇬🇧
Royal Brompton & Harefield NHS Trust,, London, United Kingdom
🇬🇧Royal Brompton Hospital, London, United Kingdom
Imperial Prostate 9 - ATLAS (Approaches To Long-Term Active Surveillance)
Not Applicable
Recruiting
- Conditions
- Prostate Cancer
- Interventions
- Diagnostic Test: MRI Scans
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2025-01-24
- Lead Sponsor
- Imperial College London
- Target Recruit Count
- 1263
- Registration Number
- NCT06280781
- Locations
- 🇬🇧
Heatherwood Hospital, Ascot, Berkshire, United Kingdom
🇬🇧Darent Valley Hospital, Dartford, Kent, United Kingdom
🇬🇧Charing Cross Hospital, London, United Kingdom
Novel Mucosal Correlates Of RSV Protection In Older Adults
Not Applicable
Recruiting
- Conditions
- Respiratory Tract Infections
- Interventions
- Biological: RSV A Memphis 37
- First Posted Date
- 2024-02-23
- Last Posted Date
- 2024-06-10
- Lead Sponsor
- Imperial College London
- Target Recruit Count
- 20
- Registration Number
- NCT06274619
- Locations
- 🇬🇧
Imperial Clinical Research Facility, Imperial College Healthcare NHS Trust, London, United Kingdom
MicroRNAs as Bile-based Biomarkers in Pancreaticobiliary Cancers
Completed
- Conditions
- Gallstone DiseaseBiliary StrictureAmpullary CancerPancreatic CancerCholangiocarcinoma
- Interventions
- Diagnostic Test: Small RNA Sequencing and Validation of candidate miRNAs
- First Posted Date
- 2024-02-14
- Last Posted Date
- 2024-02-14
- Lead Sponsor
- Imperial College London
- Target Recruit Count
- 229
- Registration Number
- NCT06258824
- Locations
- 🇬🇧
Imperial College Healthcare NHS Trust, London, United Kingdom
PsilOCD: A Pharmacological-Challenge Feasibility Study
- First Posted Date
- 2024-02-14
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Imperial College London
- Target Recruit Count
- 19
- Registration Number
- NCT06258031
- Locations
- 🇬🇧
CIPPRes Clinic, London, United Kingdom
Longitudinal Preschool Wheeze Biomarker Study
Recruiting
- Conditions
- Wheezing
- Interventions
- Procedure: Bronchoscopy, with bronchoalveolar lavage and endobronchial biopsyDiagnostic Test: Skin prick testDiagnostic Test: Finger prick blood testDiagnostic Test: Forced oscillation technique (FOT)Procedure: Sputum inductionDiagnostic Test: Oropharyngeal swab
- First Posted Date
- 2024-02-01
- Last Posted Date
- 2024-04-29
- Lead Sponsor
- Imperial College London
- Target Recruit Count
- 150
- Registration Number
- NCT06237660
- Locations
- 🇬🇧
Royal Brompton Hospital, London, United Kingdom
A Study of Etoposide-carboplatin in Combination With Pembrolizumab and Lenvatinib Maintenance in HG-NETs
Phase 2
Recruiting
- Conditions
- Neuroendocrine Tumors
- Interventions
- Combination Product: Pembrolizumab in combination with carboplatin and etoposide chemotherapy followed by pembrolizumab and lenvatinib maintenance therapy
- First Posted Date
- 2024-01-30
- Last Posted Date
- 2025-01-30
- Lead Sponsor
- Imperial College London
- Target Recruit Count
- 20
- Registration Number
- NCT06232564
- Locations
- 🇬🇧
Imperial College Healthcare NHS Trust, London, United Kingdom
Explore the Efficacy and Mechanism of Action of Tezepelumab in Eosinophilic Granulomatosis With Polyangiitis
Phase 2
- Conditions
- EGPA - Eosinophilic Granulomatosis With Polyangiitis
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-01-30
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- Imperial College London
- Target Recruit Count
- 66
- Registration Number
- NCT06230354
- Locations
- 🇬🇧
Royal Brompton Hospital - Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom
🇬🇧Barts Health NHS Trust, London, United Kingdom
🇬🇧Liverpool University Hospitals NHS Foundation Trust, Liverpool, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath